semaj83/ctmatch_classification huggingface dataset:
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 21.0-64.0,  Insomnia Male or female between the ages of 21and 64 years, inclusive Women must use a medically acceptable form of contraception during the entire study period, or: be surgically sterilized, post-menopausal, agree to use double-barrier contraception throughout the study period, or must have a negative urine pregnancy test prior to randomization Must meet the diagnostic requirements of Generalized Anxiety Disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders Score at least 18 on the Hamilton Rating Scale for Anxiety (HAM-A) Must be either newly diagnosed or show symptoms of relapse during a period of no drug therapy for anxiety Subject must experience sleep disturbances at least three nights per week, for at least one month prior to study entry, based on historical data Subject must be stabilized on all long-term medication therapy for at least one month prior to study entry History of Post-Traumatic Stress Disorder Concomitant Major Depressive Disorder or Bipolar Disorder Any abnormal pre-study laboratory values that require clinical intervention
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 6.0-17.0,  Attention Deficit Hyperactivity Disorder Male or female between the ages of 6 and 17 years, inclusive Children with diagnosed ADHD (as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision [DSM-IV-TR] criteria) Complaint of childhood insomnia as defined by repeated difficulty with sleep initiation or consolidation that occurs despite adequate age, appropriate time, and opportunity for sleep The sleep disturbance must not be attributable to either the direct physiologic effect of drug abuse or misuse of a prescribed medication Subjects should be stabilized on all long-term therapy, including treatment of ADHD, for at least one month prior to study entry Subjects, if females of childbearing potential (as determined by the initiation of menses), must have confirmed negative pregnancy test prior to randomization and be using a recognized effective method of birth control (oral, implant, depot or transdermal oestroprogestatives, intrauterine device, double-barrier with spermicide). Abstinence is an acceptable method of birth control for this study  Mental retardation Autistic spectrum disorder A history of sleep apnea A history of bipolar disorder, conduct disorder, major depression, or generalized anxiety disorder (not obsessive compulsive disorder), as determined by clinical interview and DSM-IV-TR Current history of substance abuse/dependence Known hypersensitivity to zolpidem or previous adverse experience with zolpidem Pregnant or breast-feeding Current use of hypnotics, antihistamines, melatonin, herbal products, or other sleep aids
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 13.0-17.0,  Bipolar Disorder Between the ages of 13 years, 0 months and 17 years, 11 months Meets The Diagnostic and Statistical Manual of Mental Disorders IV for either of the following conditions: bipolar I or bipolar II disorder with a manic, mixed, or hypomanic episode within 3 months of study entry; or a depressed episode within 3 months of study entry with a prior history of a manic, hypomanic, or mixed episode (if the participant only meets for a current hypomanic episode, there must also be a history of at least one prior depressive, manic, or mixed episode) Has experienced severe depression, hypomania, or mania symptoms for a period of at least 1 week within the 3 months prior to study entry Lives with at least one biological or step-parent who is available and willing to participate in treatment (parents not currently living with the adolescent participant may also participate)  Currently in full recovery (experienced minimal symptoms for at least 8 continuous weeks) Meets Diagnostic and Statistical Manual of Mental Disorders, IV for substance abuse disorder or substance dependence disorder within 3 months of study entry (based on the Kiddie Schedule for Affective Disorders and Schizophrenia Present and Lifetime Version ) Meets current for bipolar, not otherwise specified, or substance-induced mood disorder Diagnosis of mental retardation, autism, or organic central nervous system disorder Severe, unremitting psychosis that is unresponsive to neuroleptic medications, and has lasted more than 3 months Requires extended inpatient treatment (although participant can be hospitalized at the time of intake into the study) Current life-threatening eating disorder, neurological condition, or other medical problem that requires immediate treatment Exhibits or expresses serious homicidal tendencies Victim of current sexual or physical abuse by parents or is in an environment marked by domestic violence among the parents or step-parents
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Post-Traumatic Stress Disorder Depression Exposure to an interpersonal traumatic event Diagnosis of depression or PTSD (threshold or subthreshold) Functional literacy  Apparent incoherence or disorientation Apparent intoxication at recruitment Hearing impairment
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Generalized Anxiety Disorder Bipolar Disorder Male and female outpatients, aged 18 to 75 years Diagnosis of Bipolar Disorder (Bipolar I or Bipolar II) Current diagnosis of Generalized Anxiety Disorder (GAD) Participants must be on at least one of the following mood stabilizers at steady dose for at least 4 weeks prior to randomization: lithium with blood levels between 0.4-1.4 meq/L, valproic acid/divalproate sodium (with levels between 50-150 ugm/dl) carbamazepine (blood levels between 4-12 mcg/ml), or lamotrigine (dosed 50-400 mg/day)  Pregnant or lactating women or others not using acceptable means of birth control (e.g., IUD, oral contraceptives, barrier devices, condoms and foam, implanted progesterone rods stabilized for at least 3 months) Patients with current or history of schizophrenia, or patients with current mania, hypomania at study entry. Lifetime psychosis and dementia are exclusionary Patients with current obsessive-compulsive disorder or posttraumatic stress disorder are excluded Patients with a history of alcohol or substance abuse or dependence within the last three months Patients with significant unstable medical illness likely to result in hospitalization or acute medical care. In addition, patients with an established diagnosis of diabetes mellitus are excluded Current cognitive behavioral therapy directed toward the treatment of generalized anxiety disorder History of hypersensitivity to or lack of response to ziprasidone Concomitant treatment with other typical or atypical antipsychotics; patients should be off other typical or atypical antipsychotics for at least one week prior to study baseline Patients with significant suicidal ideation or who have enacted suicidal behaviors within 3 months prior to intake will be excluded from study participation and referred for appropriate clinical intervention Patients who have had a psychiatric hospitalization (including for bipolar disorder) in the past 3 months are excluded
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Insomnia Insomnia as defined by DSM-IV and supported by subject diary Male or female between the ages of 18-64 years Body mass index (BMI) between 18-34 kg/m^2 Females of childbearing potential must use a medically acceptable method of contraception Capable of understanding and willing to comply with study procedures and has provided informed consent  Females who are pregnant, breast-feeding or have a positive pregnancy test Any circadian rhythm disorder including planned travel across several time zones during the study period Known hypersensitivity to Zolpidem Has performed regular shift work with the past several months prior to screening An acute clinically significant illness or surgery as determined by the PI within 30 days of screening Patients that have used any central nervous system (CNS) medication or other medication known to impact the sleep/wake cycle A history of psychiatric disorder as defined by DSM-IV A history of drug addiction or alcohol abuse Any current significant disease, unless adequately controlled with a protocol allowed medication Known history of HIV or Hepatitis B or C
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Sleep Initiation and Maintenance Disorders Written informed consent is obtained The patient is an outpatient, man or woman of any ethnic origin, 18-75 years of age (inclusive) Patient reports insomnia for at least six months, and insomnia causes the patient distress The Investigator determines that the patient meets diagnostic for Chronic Insomnia according to International Classification of Sleep Disorders (ICSD) criteria Sleep diary based screening shows sleep onset latency >30 minutes, and /or wake after sleep onset >30 minutes per night at least 3 nights per week, with combined wake-time-in-bed _> 45 minutes The patient is in good health as determined by a medical and psychiatric history, and physical examination Women must be surgically sterile, 2 years post-menopausal, or if of child-bearing potential, using a medically accepted method of birth control, and agree to continued use of this method for the duration of the study The patient is willing and able to comply with study restrictions and to attend regularly scheduled clinic visits as specified in this protocol  Has any clinically significant, uncontrolled medical or psychiatric conditions. (treated or untreated) Has a probable diagnosis of a current sleep disorder other than Chronic Insomnia Used any prescription drugs disallowed by the protocol or clinically significant use of over-the counter(OTC) drugs within 14 days before the screening visit Has a history of alcohol, narcotic, or any other abuse as defined by the DSM-V Has a clinically significant deviation from normal in the physical examination Is a pregnant or lactating woman. (Any woman becoming pregnant during the study will be withdrawn from the study.) Has any disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery and succinic semialdehyde dehydrogenase deficiency) Has a known clinically significant drug sensitivity to sodium oxybate or sedative hypnotics
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Bipolar Depression A principal diagnosis of bipolar 1 or II disorder Ages 18-60 Physically healthy Outpatient status Montgomery-Asberg Rating Scale (MADRS) Score greater than or equal to 15 BMI 23-30 Able and willing to give written informed consent  Prior history of diabetes (types I or II) BMI>30 Non-fasting blood glucose >124 Fasting blood glucose >125 or random blood glucose >200 Presence of dyslipidemia (baseline total cholesterol >240, HDL<50, LDL>160, triglycerides >199) Current or past history of a non-affective psychotic disorder Alcohol or other substance abuse or dependence in the 6 months prior to the evaluation (except for caffeine) Current use of any nicotine products Schizoid, schizotypal, or borderline personality disorder Treatment with olanzapine in the prior 3 months or any history of non
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 12.0-21.0,  Bipolar Disorder Cannabis-Related Disorder Inclusion/  To be included, all subjects must… have an authorized parent/legal guardian who understands the nature of the study and who provides written informed consent if the study subject is younger than 18 years of age. Additionally, each subject must provide assent to the study be fluent in English be 12 to 21 years of age, inclusive be using a medically accepted means of contraception (i.e., oral contraceptives and barrier methods (diaphragm or condom), medroxyprogesterone acetate injectable suspension, abstinence) if female and of menarche. Oral contraceptives alone are not acceptable means of contraception because concomitant use of topiramate and low estrogen oral contraceptive pills may lead to oral contraceptive failure have a diagnosis of bipolar I disorder in a current manic or mixed episode, in addition to a cannabis use disorder (which includes abuse or dependence) within 28 days prior to screening, as determined by the WASH-U-KSADS have an initial YMRS total score of >16 at screening and baselines use cannabis a minimum of twice per week on average during the 28 days prior to screening Subjects will not be eligible for participation if they… have a known history of mental retardation
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 10.0-18.0,  Bipolar Disorder Weight Gain Male or female patients, ages 10-18 years Female patients of menarche must be using a medically accepted means of contraception (e.g. oral contraceptives, Depo-Provera, abstinence) Each patient's authorized legal guardian must understand the nature of the study and must provide written informed consent. Each patient must also give assent to study participation Patients must have a diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV-TR) bipolar disorder, type I and currently display an acute manic or mixed episode as determined by K-SADS (Geller et al 2000) Patients must have a baseline (day 0) Young Mania Rating Scale score of at least 16 Subjects should be fluent in English  Female patients who are either pregnant or lactating Clinically significant or unstable hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, hematologic or other systemic medical conditions Any history of current or past diabetes that has been treated with pharmacological intervention Neurological disorders including epilepsy, stroke, or severe head trauma Clinically significant laboratory abnormalities (> 3 times upper limit of normal), on any of the following tests: CBC with differential, electrolytes, BUN, creatinine, hepatic transaminases, lipid profile, fasting glucose, urinalysis, or thyroid indices. Clinically abnormal ECG Manic or mixed episode due to a general medical condition or substance-induced mania (DSM-IV-TR) Mental retardation (IQ <70) History of hypersensitivity to or intolerance of olanzapine or topiramate Prior history of olanzapine or topiramate non-response or allergic reaction DSM-IV substance (except nicotine or caffeine) dependence within the past 3 months
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Bipolar Disorder Mania Diagnosis of Bipolar 1 Disorder Hospitalized or in the process of being hospitalized for a manic or mixed episode  History of rapid cycling History of hypersensitivity or adverse reaction to lithium
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Spinal Cord Injuries Subjects of either gender and 18 years of age (preferably 10 males and females each) Subjects with chronic spinal cord injury (defined as 12 months or more post spinal cord injury), as confirmed by a MRI Subjects with neurological status: ASIA A, B or C Subjects must be able to read, understand, and complete the VAS Subjects who have voluntarily signed* and dated* an informed consent form, approved by an IEC/IRB, prior to any study-specific procedures *If a subject consents to participation but is not in a position to personally sign and date the informed consent form because of his or her physical condition, the consent must be confirmed at the time of consent orally, signed on behalf by the subject's relative, and by an impartial witness who is present throughout the whole informed consent process  Subjects are excluded if they have a history of hypersensitivity to lithium significant renal, cardiovascular, hepatic and psychiatric diseases significant medical diseases or infection brain injury Addison's disease debilitation or dehydration recently taken or are taking diuretics or other drugs with known interaction with lithium, such as tricyclic antidepressants, NSAIDs and tetracycline a history of alcohol abuse or drug abuse, or if they are pregnant or lactating women
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 12.0-18.0,  Insomnia patients diagnosed as having nonorganic insomnia of nonorganic sleep disorder in ICD10 patients whose age at the time of obtaining consent is 12 years or over and 18 years or below  patients with schizophrenia or manic-depressive illness patients with insomnia caused by physical diseases patients having a history of hypersensitivity to zolpidem patients with attention-deficit hyperactivity disorder